Robert Hewlett
Pulmonary Disease · Newport Beach, CANPI 1265441174
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Boehringer Ingelheim at 26.3% of the total. Reporting peaked in 2019 at $2,168 and has fallen 93.1% since, to $150 in 2024.
Across 219 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- AstraZeneca$928
- GSK$550
- Grifols USA, LLC$377
- Mylan Specialty L.p.$277
- Takeda Pharmaceuticals U.S.A., Inc.$197
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,27198%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 33 | $1,414 |
| AstraZeneca | 47 | $928 |
| GSK | 31 | $550 |
| Grifols USA, LLC | 15 | $377 |
| Mylan Specialty L.p. | 15 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $197 |
| Pulmonx Corporation | 3 | $179 |
| Genentech USA, Inc. | 12 | $158 |
| Insmed, Inc. | 4 | $158 |
| Sunovion Pharmaceuticals Inc. | 7 | $157 |
| Regeneron Healthcare Solutions, Inc. | 4 | $137 |
| Philips North America LLC | 6 | $129 |
| Advanced Respiratory, Inc | 4 | $84 |
| Amgen | 3 | $80 |
| Johnson & Johnson | 3 | $61 |
| Electromed, Inc. | 4 | $49 |
| Octapharma USA, Inc. | 1 | $49 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Sanofi | 2 | $42 |
| Pfizer | 2 | $41 |
| Merck | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| CSL Behring | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Shionogi Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Endogastric Solutions, Inc | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,371 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Newport Beach
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.